The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.
 
Gregory James Gerstner
Employment - illinois Cancer Care
Leadership - illinois Cancer Care
Stock and Other Ownership Interests - illinois Cancer Care
Research Funding - illinois Cancer Care
 
Suresh S. Ramalingam
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; GlaxoSmithKline; Lilly/ImClone; Merck; Mirati Therapeutics; Takeda
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - American Cancer Society
 
Aaron E. Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Leica Biosystems; Lilly; MorphoSys; Novartis; Novocure; Oncocyte; Pfizer; Sanofi/Regeneron
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; WindMIL
 
Charles Michael Farber
Stock and Other Ownership Interests - Alexion Pharmaceuticals
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Gilead Sciences; Morphosys/Incyte; TG Therapeutics
Speakers' Bureau - ADC Therapeutics; Genentech; Gilead Sciences; Morphosys/Incyte; Seagan; TG Therapeutics
 
Neil Morganstein
No Relationships to Disclose
 
Rachel E. Sanborn
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech/Roche; Janssen Oncology; Macrogenics; Mirati Therapeutics; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - AstraZeneca
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); BeiGene; Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Ranjan Pathak
Honoraria - Onc.AI
 
Chao Hui Huang
Stock and Other Ownership Interests - Vanguard Funds
Honoraria - Ipsen
Consulting or Advisory Role - Biodesix; Ipsen
Speakers' Bureau - Curio Science; Targeted Oncology
Research Funding - Bayer (Inst); Benta Pharma Industries (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Regenxbio (Inst)
 
Surya Vangala
Employment - Advaxis
Stock and Other Ownership Interests - Advaxis; Advaxis
 
Megan Parsi
Employment - Advaxis
Stock and Other Ownership Interests - Advaxis; Bristol-Myers Squibb
Consulting or Advisory Role - Oxford Global
 
Cristiane Metran
No Relationships to Disclose
 
Andres A. Gutierrez
Employment - Advaxis
Leadership - Advaxis
Stock and Other Ownership Interests - Advaxis
Honoraria - Advaxis
 
Jonathan W. Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca